Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARE trial of DHEA augmentation for treatment-resistant depression
2024-517963-21-00Phase 3Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing Biosteron augmentation with Placebo augmentation (2 arms). Primary endpoint: Change in MADRS score. Planned start Nov 2025; status: authorised.
02
Drugs
prasterone
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-517963-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517963-21-00.